07:46 AM EDT, 03/17/2026 (MT Newswires) -- Pulse Biosciences ( PLSE ) said Tuesday it will focus more resources on developing its nPulse cardiac catheter ablation system following encouraging results from a European study in patients with atrial fibrillation.

The company said data from more than 150 patients showed strong results, including high success rates and low complication levels. The treatment uses the company's nPulse platform, which delivers very short electrical pulses to treat hear rhythm problems.

Pulse Biosciences ( PLSE ) said most of its research and development spending will now be directed toward the cardiac catheter program and upcoming key clinical studies in the US and Europe needed for regulatory approval.

The company will scale back spending on some other programs, including surgical and soft-tissue treatments, to support this focus, it said.